Abstract
Tumour necrosis factor (TNF-α/cachectin, TNF) was discovered originally as a factor displaying cytotoxic/cytostatic effects on transformed cells in vitro and necrotizing activity on certain transplantable tumours in vivo (Carswell et al. 1975). In later studies, TNF was shown to be the primary mediator of wasting accompanying chronic invasive diseases (Beutler et al. 1985; Tracey et al. 1986). Acting in concert with other members of the cytokine network, TNF has now been clearly established as a central regulator of inflammation and immunity, mainly
Table 1. In vivo activities of TNF — context, rate and duration of TNF — synthesis
Homeostasis |
Differentiation — tissue remodelling |
Induction of cytokine cascades — synergy |
Inflammation |
Cellular immunity — infectious diseases |
Cytotoxicity — tissue destruction |
Vascular thrombosis and tumour necrosis |
Cachexia and wasting toxicity |
Shock and death |
by modulating the functional state of cells that participate in such processes (reviewed by Beutler and Cerami 1989; Old 1990). For example, it has been shown that TNF augments the cytotoxicity of macrophages (Esparza et al. 1987), induces neutrophil adhesion and activation (Gamble et al. 1985) and regulates T and B cell growth and differentiation (Shalaby et al. 1988). The cell-specific effects of TNF are also exerted in a number of nonimmune cell types. The hemostatic properties of vascular endothelial cells are found to be modulated by TNF which induces the production of procoagulant activity (Nawroth and Stern 1986) and enhances the expression of adhesion molecules that bind neutrophils and monocytes (Gamble et al. 1985). Moreover, TNF is shown to be a growth factor for normal fibroblasts (Vilcek et al. 1986) and thymocytes (Ranges et al. 1988) and to interfere with the metabolism of adipocytes (Semb et al. 1987). In response to TNF many cell types are found to increase the production of several other factors, including IL-6, IL-1, colony stimulating factors, collagenase, PGE2, c fos, c-myc and histocompatibility antigens. Fine tuning of such circuits is very important to the defence of the host and to the restoration of homeostasis in the body following a microbial infection or a tissue injury.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beutler B, Cerami A (1989) The biology of cachectin/TNF- a primary mediator of the host response. Ann Rev Immunol 7: 625–655
Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232: 977–980
Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetcher H (1990) Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87: 3127–3131
Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-la. Clin Exp Immunol 73: 449–455
Butler DM, Piccoli DS, Hart PH, Hamilton JA (1988) Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. J Rheumatology 15: 1463–1470
Caput D, Beutler B, Hartog K, Thayer R, Shimer SB, Cerami A (1986) Identification of a common nucleotide sequence in the 3’-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 83: 1670–1674
Carswell E, Old L, Cassel R, Green S, Fiore N, Williamson B (1975) An endotoxin serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 72: 36–66
Engelman H, Aderka D, Rubinstein M, Rotman D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264: 11974–11980
Esparza I, Mannel D, Ruppel A, Falk W, Krammer PH (1987) Interferongamma (IFN-y) and lymphotoxin (LT) or tumor necrosis factor ( TNF) synergize to activate macrophages for tumoricidal and schistosomulicidal functions. Lymphokine Res 6: 1715.
Gamble JR, Harlan JM, Klebanoff SJ, Lopez AF, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82: 8667–8671
Gitter BD, Labus JM, Lees SL, Scheetz ME (1989) Characteristics of human synovial fibroblast activation by IL-113 and TNFa. Immunology 66: 196–200
Grau GE, Piguet PF, Vassali P, Lambert P-H (1989) Tumor necrosis factor and other cytokines in cerebral malaria: experimental and clinical data Immunol 112: 49–70
Greaves DR, Wilson FD, Lang G, Kioussis D (1989) Human CD2 3’-flanking sequences confer high-level, T cell specific, position independent gene expression in transgenic mice. Cell 56: 979–986
Hammer RE, Malka SD, Richardson JA, Tang JP, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human 132m: an animal model of HLA-B27-associated human disorders. Cell 63: 1099–1112
Han J, Brown T, Beutler B (1990) Endotoxin-responsive sequences control cachectin/tumor necrosis factor at the translational level. J Exp Med 171: 465–475
Hang LM, Theofilopoulos AN, Dixon Ft (1982) A spontaneous rheumatoid arthritis-like disease in MRL/1 mice. J Exp Med 155: 1690–1701
Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C (1990) Genes encoding tumor necrosis factor a and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 7: 2239–2243
Husby G, Williams RC Jr (1988) Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1: 363–371
Iwakura Y, Tosu M, Yoshida E, Takiguchi M, Sato K, Kitajima I, Nishioka K, Yamamoto K, Takeda T, Hatanaka M, Yamamoto H, Sekiguchi T (1991) Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 253: 1026–1028
Jasin HE (1988) Chronic arthritis in rabbits. Meth Enzymol 162: 379–385
Jue DM, Sherry B, Luedke C, Manogue KR, Cerami A (1990) Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin stimulated macrophages. Biochemistry 29: 8371–8377
Keffer, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 13: 4025–4031
Kinkhabwala M, Sehajpal P, Skolnik E, Smith D, Sharma VK, Vlassara H, Cerami A, Suthanthiran M (1990) A novel addition to the T cell repertory; cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med 171: 941–946
Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, Squires CH, Thompson RC, Vannice JL (1990) A second tumor necrosis factor receptor gene product can shed a naturally occuring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87: 8331–8335
Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45–53
Kruys V, Matinx O, Shaw G, Deschamps J, Huez G (1989) Translational blockade imposed by cytokine-derived UA-rich sequences. Science 245: 852–855
Lewis M, Tartaglia TA, Lee A, Bennett GL, Rice GC, Wong GHW, Chen EY, Goeddel DV (1991) Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 88: 2830–2834
Liu CC, Detmers PA, Jiang S, Young JD-E (1989) Identification and characterization of a membrane-bound cytotoxin of murine cytolytic lymphocytes that is related to tumor necrosis factor/cachectin. Proc Natl Acad Sci USA 86: 3286–3290
Luettig B, Decker T, Lohmann-Matthes ML (1989) Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J Immunol 143: 4034–4038
Macnaul KL, Hutchinson NI, Parsons JN, Bayne EK, Tocci MJ (1990) Analysis of IL-1 and TNF-a gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J Immunol 145: 4154–4166
Nawroth PP, Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163: 740–745
Old LJ (1990) Tumor necrosis factor. In: Bonavida B, Granger G (eds) Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy. Basel, Karger, pp 1–30
Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Celi 50: 555–563
Osborn L, Kunkel S, Nabel GJ (1989) Tumor necrosis factor a and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor KB. Proc Natl Acad Sci USA 86: 2336–2340
Peck R, Brockhaus M, Frey JR (1989) Cell surface tumor necrosis factor ( TNF) acounts for monocyte-and lymphocyte-mediated killing of TNF-resistant target cells. Cell Immunol 122: 1–10
Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M (1990) A non-secretable cell surface mutant of tumour necrosis factor ( TNF) kills by cell to cell contact. Cell 63: 251–258
Piguet PF, Grau GE, Allet B, Vassalli P (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166: 1280–1289
Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172: 599–607
Ranges GE, Zlotnik A, Espevik T, Dinarello CA, Cerami A, Palladino MAJr (1988) Tumor necrosis factor a/cachectin is a growth factor for thymocytes. J Exp Med 167: 1472–1478
Ridge SC, Oronsky AL, Kerwar SS (1988a) Type II collagen-induced arthritis in rats. Meth Enzymol 162: 355–360
Ridge SC, Zabriskie JB, Oronsky AL, Kerwar SS (1988b) Streptococcal cell wall-induced arthritis in rats. Meth Enzymol 162: 373–379
Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor a but not tumor necrosis factor [3 in rheumatoid arthritis synovial fluid and serum. Arthritis and Rheumatism 31: 1041–1045
Seckinger P, Isaaz S, Dayer JM (1989) Purification and biologic characterization of a specific tumor necrosis factor-a inhibitor. J Biol Chem 264: 11966–11973
Semb H, Peterson J, Tavernier J, Olivecrona T (1987)Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 262: 8390–8394
Shalaby MR, Espevic T, Rice GC, Ammann AJ, Figari IS, Ranges GE, Palladino MAJr (1988) The involvement of human tumor necrosis factors-a and -(3 in the mixed lymphocyte reaction. J Immunol 141: 499–503
Shaw G, Kamen R (1986) A conserved AU sequence from the 3’-untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659–667
Smith R, Baglioni C (1989) Multimeric structure of the tumor necrosis factor receptor of HeLa cells. J Biol Chem 264: 14646–14652
Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Goeddel DV (1991) The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88: 9292–9296
Taurog JD, Argentiery DC, McReynolds RA (1988) Adjuvant arthritis. Meth Enzymol 162: 339–355
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark 1W, Hariri RJ, Fahey III TJ, Zentella A, Albert JD, Shires GT, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474
Trentham DE (1982) Collagen arthritis as a relevant model for rheumatoid arthritis. Arthr. Rheumatism 25: 911–915
Vilcek J, Palombella VJ, Henriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163: 632–643
Wooley PH (1988) Collagen-induced arthritis in the mouse. Meth Enzymol 162: 361–373
Yocum DE, Esparza L, Dubry S, Benjamin JB, Volz R, Scuderi P (1989) Characteristics of tumor necrosis factor production in rheumatoid arthritis. Cellular Immunol 122: 131–145
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kollias, G.A. (1993). Transgenic Models of Chronic Arthritis and of Systemic Tumour Necrosis Factor-Mediated Disease in Mice Expressing Human Tumour Necrosis Factor. In: Wagner, E.F., Theuring, F. (eds) Transgenic Animals as Model Systems for Human Diseases. Schering Foundation Workshop, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-02925-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-02925-1_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-02927-5
Online ISBN: 978-3-662-02925-1
eBook Packages: Springer Book Archive